Detecting Renal Allograft Inflammation Using Quantitative Urine Metabolomics and CXCL10

Julie Ho, MD,1 Atul Sharma, MD,2,3,4 Rupasri Mandal, PhD,5 David S. Wishart, PhD,5,6,7 Chris Wiebe, MD,1 Leroy Storsley, MD,1 Martin Karpinski, MD,1 Ian W. Gibson, MD,6 Peter W. Nickerson, MD,1 and David N. Rush, MD1

Background. The goal of this study was to characterize urinary metabolomics for the noninvasive detection of cellular inflammation and to determine if adding urinary chemokine ligand 10 (CXCL10) improves the overall diagnostic discrimination.

Methods. Urines (n = 137) were obtained before biopsy in 113 patients with no (n = 66), mild (borderline or subclinical; n = 58), or severe (clinical; n = 13) rejection from a prospective cohort of adult renal transplant patients (n = 113). Targeted, quantitative metabolomics was performed with direct flow injection tandem mass spectrometry using multiple reaction monitoring (ABI 4000 Q-Trap). Urine CXCL10 was measured by enzyme-linked immunosorbent assay. A projection on latent structures discriminant analysis was performed and validated using leave-one-out cross-validation, and an optimal 2-component model developed. Chemokine ligand 10 area under the curve (AUC) was determined and net reclassification index and integrated discrimination index analyses were performed. Results. PLS2 demonstrated that urinary metabolites moderately discriminated the 3 groups (Cohen’s κ, 0.601; 95% confidence interval [95% CI], 0.46-0.74; P < 0.001). Using binary classifiers, urinary metabolites and CXCL10 demonstrated an AUC of 0.81 (95% CI, 0.74-0.88) and 0.76 (95% CI, 0.68-0.84), respectively, and a combined AUC of 0.84 (95% CI, 0.78-0.91) for detecting alloimmune inflammation that was improved by net reclassification index and integrated discrimination index analyses. Urinary CXCL10 was the best univariate discriminator, followed by acylcarnitines and hexose.

Conclusions. Urinary metabolomics can noninvasively discriminate noninflamed renal allografts from those with subclinical and clinical inflammation, and the addition of urine CXCL10 had a modest but significant effect on overall diagnostic performance. These data suggest that urinary metabolomics and CXCL10 may be useful for noninvasive monitoring of alloimmune inflammation in renal transplant patients.

(A Transplantation 2016;2: e78; doi: 10.1097/TXD.0000000000000589. Published online 19 May 2016.)
subclinically—that is, in the absence of graft dysfunction. Moreover, subclinical TCMR is found in up to 30% of patients that undergo surveillance biopsies and is associated with the development of interstitial fibrosis and tubular atrophy (IFTA), de novo donor-specific antibodies, and AMR, all of which are associated with graft loss. The inability of serum creatinine to detect subclinical TCMR combined with the limitations of surveillance biopsies (morbidity, sampling error, and cost) argue for the development of noninvasive tests for renal allograft monitoring to guide the titration of immunosuppression.

Renal allograft inflammation has been shown to down-regulate tubular epithelial proteins involved in solute and water transport in both rodent and human models, which may alter the urinary metabolome. To this end, several groups have evaluated urinary metabolomics as a potential noninvasive marker of renal allograft inflammation using different approaches. Similarly, urinary chemokines have been evaluated as noninvasive markers for rejection. Urine chemokine ligand 10 (CXCL10) has been found to be a promising rejection marker that rises before serum creatinine, decreases after treatment of rejection, and is sufficiently sensitive to detect both borderline and subclinical tubulitis.

Taken together, urine CXCL10 has been shown to outperform standard of care monitoring; however, urine CXCL10 only detects subclinical tubulitis with an area under the curve (AUC) of 0.69. Therefore, the goal was to characterize urinary metabolomics for the noninvasive detection of rejection and determine if metabolomics can be added to urine CXCL10 to improve its overall diagnostic performance.

METHODS

Patients and Biopsies

This study was approved by the ethics committee of the University of Manitoba and all participating patients gave written informed consent. This is a retrospective analysis of a prospective, observational selected cohort of adult renal transplant patients consisting of 137 renal transplant biopsies with paired urine samples obtained in 113 patients with surveillance or clinically indicated biopsies. The remaining biopsies (n = 15) were performed for indication of biopsy-proven ATN and serum creatinine of 20% or greater from baseline (n = 14).

Other inflammatory states, such as urinary tract infection, cytomegalovirus, and polymavirus, were excluded from all groups.

A subsequent analysis to evaluate the potential confounding influence of acute tubular necrosis (ATN) was performed in patients with indication of biopsy-proven ATN and serum creatinine of 20% or greater from baseline (n = 14).

Urine Collection

Midstream urine samples were obtained immediately before surveillance or clinically indicated biopsies were performed and were frozen at −80°C until analysis.

Urine Metabolome Analysis

Metabolomics was performed by direct flow injection mass spectrometry (MS) using the commercially available Absolute-IDQ kit (Biocrates Life Sciences AG, Austria), in combination with an ABI 4000 Q-Trap (Applied Biosystems/MDS Sciex) mass spectrometer as previously described. Briefly, urine samples were thawed on ice, vortexed, and then centrifuged at 13 000 rpm. Ten microliters of urine supernatant was loaded onto the kit’s filter paper substrate and dried under nitrogen. Metabolite extraction was achieved using methanol containing 5 mM ammonium acetate. A standard flow injection protocol consisting of two 20-μL injections (1 for the positive and 1 for the negative ion detection mode) was applied for all measurements. Urine metabolites were quantified by multiple reaction monitoring MS/MS using isotope-labeled internal standards from the kit plate filter.

Metabolites below the limit of detection were analyzed as limit of detection/2, and metabolite concentrations were normalized by urine creatinine to correct for dilution. The Biocrates MetIQ software was used to control the assay workflow from sample registration to automated calculation of metabolite concentrations to the export of data into other data analysis programs. An average of 95 metabolites was measured in each urine sample (range, 75-98) from the following classes: amino acids, acylcarnitines, hexose, creatine, glycercophospholipids, and sphingolipids. Preliminary analysis demonstrated that only acylcarnitines and hexose were discriminatory (Table S1, SDC, http://links.lww.com/TXD/A24), so these were used for subsequent analyses (n = 34, plus creatinine).
TABLE 1.
Patient characteristics

| Characteristic | Total  | No inflammation | Mild inflammation | Severe inflammation |
|---------------|--------|----------------|------------------|--------------------|
| Patient age, y | 44 ± 12| 44 ± 12        | 46 ± 12          | 46 ± 12            |
| Ethnicity (white, %) | 103 (75) | 25 (76)       | 20 (61)         | 19 (62)           |
| Panel-reactive antibody, % | 6 ± 19 | 7 ± 22         | 9 ± 21           | 4 ± 13            |
| Total HLA mismatch | 3.4 ± 1.2 | 3.1 ± 1.2    | 3.4 ± 1.4       | 2.9 ± 1.3         |
| Donor age, y | 39 ± 15 | 33 ± 15       | 48 ± 12         | 51 ± 11           |
| Living donor (%) | 62 (45) | 17 (52)      | 14 (42)         | 7 (70)           |
| Delayed graft function (%) | 21 (15) | 2 (6)        | 5 (19)          | 1 (10)           |
| Banff i score | 1.0 ± 1.0 | 0             | 0.3 ± 0.5       | 1.1 ± 0.3         |
| Banff t score | 1.0 ± 1.1 | 0.03 ± 0.2  | 0.06 ± 0.2      | 1.3 ± 0.5         |
| Banff g score | 0.02 ± 0.1 | 0            | 0               | 0.07 ± 0.3        |
| Banff v score | 0.04 ± 0.2 | 0            | 0               | 0.07 ± 0.3        |
| Banff ci score | 0.5 ± 0.6 | 0.03 ± 0.2  | 1.1 ± 0.4       | 1.4 ± 0.5         |
| Banff ct score | 0.5 ± 0.6 | 0.2 ± 0.4  | 1.1 ± 0.4       | 1.2 ± 0.4         |
| Banff cg score | 0.02 ± 0.1 | 0            | 0               | 0.03 ± 0.2        |
| Banff cv score | 0.3 ± 0.6 | 0.07 ± 0.2  | 0.6 ± 0.7       | 1.0 ± 0.9         |
| Surveillance biopsy (%) | 122 (99) | 32 (100)    | 32 (97)        | 10 (100)          |
| Biopsy posttransplant, wk | 25 ± 24 | 21 ± 8       | 48 ± 36        | 23 ± 9           |
| Creatinine at biopsy, μmol/L | 121 ± 40 | 106 ± 24     | 125 ± 53      | 148 ± 30         |
| MDRO eGFR@ at biopsy, mL/min | 56 ± 17 | 63 ± 13      | 55 ± 17        | 45 ± 7           |
| Urine CXCL10: Cr, ng/mmol* | 1.77 ± 3.5 | 5.71 ± 7.9 | 13.4 ± 13.5 | 19.4 ± 29.2 |

Data are represented as mean ± SD or count (%).

*Modification of Diet in Renal Disease estimated Glomerular Filtration Rate

Urinary CXCL10 Analysis

Urinary CXCL10 was quantified by ELISA according to previously described protocols, on a Biorex Synergy 4 microplate reader (Gen 5 software; Fisher Scientific). The sensitivity was 1.95 pg/mL, and the intra-assay and inter-assay coefficients of variation were 3.90% and 4.54%, respectively. Urine CXCL10 was corrected for dilutional factors using urine creatinine determined from the metabo-
both IFTA groups \((P < 0.0001)\). The Banff scores were significantly different between groups, by definition. As expected, serum creatinine was significantly higher in patients with clinical rejection compared with the other groups \((P < 0.0001)\). Only 1 patient in the cohort developed a de novo donor-specific antibody. Finally, the biopsies with IFTA were done significantly later posttransplant than biopsies with inflammation.

**Urinary Metabolomics Distinguishes Alloimmune Inflammation**

The PLS2 algorithm seeks a common set of PLS components to distinguish the 3 distinct histologic phenotypes. A score plot on the first 3 PLS components (Figure 1) suggests that this PLS decomposition may be usefully applied to classify all 3 phenotypes with a single model, by using these scores as predictors in a multinomial regression model that assigns a probability for each mutually exclusive outcome. The predicted class with the highest assigned probability can then be compared with the observed histology. The performance of this 3-way classifier was measured in terms of agreement between predicted and actual phenotype using a Cohen \(\kappa\), with \(\kappa = 0.601\) (95% confidence interval [95% CI], 0.46-0.74; \(P < 0.001\)), which is substantial agreement by the Landis-Koch criteria. Encouraged by these results, we then sought to formally train a classifier using specific pairwise comparisons.

**No Inflammation Versus Mild Inflammation**

This classifier was developed by training no inflammation versus mild inflammation. The optimal 2-component model yielded an AUC of 0.78 (95% CI, 0.70-0.86), with a sensitivity of 0.67 and specificity of 0.78. These findings were confirmed by permutation testing \((P < 0.003)\) and LOOCV \((P < 0.01)\). The full PLS-DA model \((n = 34\) metabolites\) demonstrated a stepwise increase in classification scores with increasing alloimmune inflammation (data not shown).

The weighted sum of absolute regression coefficients identified the top 10 metabolites, and diagnostic performance was characterized for the top 10 (AUC, 0.77; 95% CI, 0.69-0.85; \(P < 0.001\)) and top 3 metabolites (AUC, 0.74; 95% CI, 0.65-0.83). The top 3 metabolites contributing to this classifier were hexose, C8:1, and C2 which experienced log2-fold changes of 0.65 or higher between the no inflammation and mild inflammation groups.

**No Inflammation Versus Any Inflammation**

This classifier was developed by training no inflammation versus any inflammation. The optimal 2-component model yielded an AUC of 0.81 (95% CI, 0.74-0.88) with a sensitivity of 0.76 and specificity of 0.63. These findings were confirmed by permutation testing \((P < 0.001)\) and LOOCV. When the full PLS-DA model was applied to the full data set \((n = 137\) urines\), this demonstrated a significant and step-wise increase in classification scores with increasing alloimmune inflammation (Figure 2). These findings were externally validated.
with additional severe inflammation samples (clinical rejection, n = 6; classification score, 0.72 ± 0.2; \( P = 0.0003 \) compared with no inflammation).

The weighted sum of absolute regression coefficients identified the top 10 metabolites, and diagnostic performance was characterized for the top 10 (AUC, 0.78; 95% CI, 0.71-0.86; \( P < 0.001 \)) and top 3 metabolites (AUC, 0.78; 95% CI, 0.70-0.86). The top 3 metabolites contributing to this classifier were hexose, C8:1, and C3-DC/C4-OH which experienced absolute log2-fold changes of 0.82 or higher between the no inflammation and any inflammation groups (Figure 2).

**Urine Metabolites Reflect Differential Alloimmune Inflammation Within Patients**

The histology and urine metabolite signature changed in sequential biopsies in some patients with mild subclinical inflammation that was more severe on repeat biopsy performed for graft dysfunction, whereas others had treatment of subclinical/clinical rejection that resulted in histological improvement and a metabolite signature of no inflammation (Figure 2). These observations suggest that in stable patients, the inflammation signature may precede a clinical rejection episode and that successful treatment of a rejection episode may result in normalization of the urine signal.

**Urine CXCL10**

Urine CXCL10:Cr showed a significant stepwise increase according to increasing severity of alloimmune inflammation as expected (Figure 3). Urine CXCL10:Cr alone showed similar diagnostic performance (AUC, 0.76; 95% CI, 0.68-0.84) as the urine metabolite panel (AUC, 0.81; 95% CI, 0.74-0.88). The addition of urine CXCL10 to the PLS model increased the overall diagnostic performance (combined AUC, 0.84; 95% CI, 0.78-0.91), which was a statistically significant improvement using both the DeLong test for comparing 2 correlated ROC curves (\( P < 0.05 \)) and the continuous NRI/IDI comparisons (\( P < 0.001 \)) (Figure 3).

In addition to adding urine CXCL10 to the PLS scores, urine CXCL10 was also included as an additional predictor within the standard PLS-DA analysis of none versus any inflammation. The optimal 2-component model including urine CXCL10 yielded an AUC of 0.845 (95% CI, 0.78-0.91), which was confirmed by permutation testing (\( P < 0.001 \)) and LOOCV. Interestingly, the variable importance scores demonstrated that urinary CXCL10 was the most important predictor with twice the score of the next most predictive metabolite (Table 2).

**Any Inflammation Versus ATN**

Confounding was noted when the rejection classifier was applied to patients with ATN (n = 14), with a classification score of 0.78 ± 0.2 which was significantly different from the no inflammation group (\( P < 0.0001 \)). As expected urinary CXCL10 did not distinguish ATN from rejection.\(^{37}\) For this reason, we next sought to determine if alloimmune inflammation could be distinguished from ATN. This ATN classifier was developed by training any inflammation (n = 71) versus ATN (n = 14). The 3-component model had excellent performance in discriminating ATN from any inflammation with an AUC of 1.0 (95% CI, 1-1), which was confirmed with permutation testing (\( P < 0.001 \)) and LOOCV. The ATN classifier yielded significantly different scores in patients with any inflammation versus ATN (Figure 4). Interestingly, the metabolites were different in the ATN versus rejection classifiers; and the top 5 ATN metabolites (C16.1. OH, C16, C3OH, C2, and C0) showed no overlap with the top 5 rejection metabolites.

This ATN classifier is useful for sequential application because it did not identify biopsies with no inflammation.

### TABLE 2.

| Metabolite or protein | VIP | Univariate AUC (95% CI) |
|----------------------|-----|------------------------|
| CXCL10               | 100 | 0.76 (0.68-0.84)        |
| Hexose               | 52.3| 0.65 (0.56-0.75)        |
| C8:1                 | 45.5| 0.68 (0.59-0.77)        |
| C4                   | 33.3| 0.60 (0.50-0.69)        |
| C0                   | 30.4| 0.59 (0.50-0.69)        |
| C3-DC/C4-OH          | 28.4| 0.59 (0.49-0.68)        |
| C2                   | 27.2| 0.58 (0.48-0.67)        |
| C10:1                | 26.5| 0.70 (0.62-0.79)        |
| C9                   | 21.1| 0.64 (0.55-0.74)        |
| C5.1. DC             | 20.4| 0.64 (0.55-0.74)        |

VIP, variable importance.
DISCUSSION
This study demonstrates that a quantitative urine MS metabolomic signature is capable of discriminating between grafts with no inflammation (normal histology, IFTA without inflammation) from those with subclinical inflammation (borderline inflammation with or without IFTA; subclinical TCMR), and clinical TCMR. From the panel of 34 metabolites used here, the urine metabolites that best discriminated between the various degrees of cellular inflammation in the renal allograft were the acylcarnitines and hexose. The addition of the urine chemokine protein CXCL10 improved the overall diagnostic discrimination of urine metabolites alone, and indeed was the most important predictor of alloimmune inflammation when included in the PLS-DA model. Finally, a novel ATN classifier was developed to accurately discriminate alloimmune inflammation from ATN.

Carnitine (1-3-hydroxy-4-N,N,N-trimethyaminobutyrate) is an essential metabolite required for the translocation of activated long-chain fatty acids from the cytosol to the mitochondrial matrix, where \( \beta \)-oxidation of fatty acids takes place providing energy to the cells. In humans, 75% of carnitine comes from dietary animal sources, but 25% is endogenously synthesized, primarily in the liver and kidney. The kidney recclaims filtered carnitine through the organic cation transporter 2 (OTCN2) (encoded by the SLC 22 A5 gene) present in the brush border of the proximal tubule.\(^38,39\)

The expression of gene transcripts for several organic cation transporters has been shown to be decreased in clinical TCMR in both mouse and human kidneys, as part of nonspecific tubular epithelial cell injury that occurs also in ATN.\(^3-11\) However, there are no data, to our knowledge, on the expression of the carnitine transporter OTCN2 either in animal models of renal transplantation or in human renal transplant recipients. Nevertheless, patients with mild inflammation showed an altered pattern of urine acylcarnitine excretion compared with those patients with biopsies showing no inflammation. Moreover, in severe inflammation cases with clinical rejection, the urine concentration levels of several acylcarnitines, and in particular that of the acylcarnitine C3-DC/C4-OH and C8:1, were markedly increased over that observed in patients with no or mild inflammation, consistent with a decrease in the tubular expression or function of the OTCN2 transporter, as has been reported for other cation transporters in rodents and humans.\(^3-11\)

The differences in urine carnitine excretion in patients with subclinical or clinical rejection may also be related to the composition of the cellular infiltrate in the graft. There is a preponderance of activated monocytes in clinical rejection as compared with subclinical rejection in which the infiltrating cells are mostly lymphocytes.\(^40\) Both lymphocytes and monocytes contain free carnitine and acylcarnitines, with monocytes containing approximately 4-fold more total carnitine per cell than lymphocytes.\(^41\) Moreover, monocytes activated in vitro with phorbol esters increase their free carnitine levels by greater than 50%.\(^42\) Lymphocytes and monocytes infiltrating the kidney allograft during acute rejection undergo apoptosis,\(^43\) and it is plausible therefore that the increased urinary amounts of carnitines, such as C3-DC/C4-OH, observed in clinical rejection may in part be the result of increased amounts of filtered carnitines derived from apoptotic monocytes in the graft that are not reclaimed by the decreased tubular expression of the OTCN2 transporter.

Notably, the urinary metabolite profile accurately reflected changing alloimmune inflammation in individuals with sequential biopsies. These findings are consistent with Foxall et al\(^12\) who showed that the urinary excretion of trimethylamine-N-oxide detected by nuclear magnetic resonance spectroscopy increased 2 days before a clinical
rejection episode and returned to normal after its treatment. In further support of these observations, in an experimental rat renal allograft model, Edemir et al\(^1\) showed that the downregulated expression of aquaporin 2 and epithelial Na\(^+\) channel genes that occurred with clinical rejection was increased toward normal after treatment with cyclosporine. As anticipated, the urinary CXCL10 findings were highly consistent with the reported literature.\(^2\) Interestingly, however, the urine metabolites that discriminated between inflamed and noninflamed renal parenchyma in our adult renal transplant patients were different from those observed by others.\(^12\)–\(^15\) These differences may relate to the different metabolites and platforms used for evaluation and reinforce the need for independent validation studies.

The evaluation of subclinical rejection allowed us to elucidate the interactions between alloimmune inflammation and graft function. Notably, patients with subclinical rejection had equivalent Banff scores as the clinical rejection group despite having similar graft function as those patients with no inflammation. The observed stepwise increase in the classifier scores between no inflammation, mild, and severe inflammation suggests that the rejection classifier is independent of graft function. Furthermore, both the clinical rejection and ATN groups had poor allograft function despite highly divergent Banff scores; moreover, the ATN classifier accurately distinguished these 2 groups, demonstrating that urinary metabolites reflect underlying tubular pathophysiology independent of graft function.

There are some limitations to this study. First, the number of patients is relatively small, particularly those with clinical rejection. However, these findings were validated with permutation testing, LOOCV, and additional clinical rejection samples. Second, this analysis was performed in highly selected cases and controls resulting in selection bias; and thus the diagnostic performance may be an overestimate of its performance in a larger, unselected population. Third, patients were studied predominantly in the early posttransplant period; therefore, pathologies that tend to present later (eg, recurrent glomerulonephritis, AMR) are not represented. Finally, there are no patients with inflammatory conditions, such as bacterial or viral infections as controls. These discovery-based metabolomic studies require validation in independent cohorts.

Nevertheless, despite the above limitations, we believe that quantitative MS-based urine metabolomics may be useful for the diagnosis of renal allograft inflammation. Importantly, this approach to biomarker development demonstrates that urine metabolomics in conjunction with urine CXCL10 improves the overall diagnostic discrimination and that sequential application of different metabolite classifiers can be used to rule out confounders, such as ATN. Ultimately, noninvasive strategies for the early detection of alloimmune inflammation may improve long-term graft survival for renal transplant patients.

**ACKNOWLEDGMENT**

The authors would like to acknowledge Evelyn Roloff for her assistance in preparation of the article.

**REFERENCES**

1. El-Zoghby ZM, Stegel MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9:527–535.
2. Rush DJ, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant. 2007;7:2538–2545.
3. Rush DN, Cockfield SM, Nickerson PW, et al. Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil. Transplantation. 2009;88:1203–1208.
4. Amico P, Hirt-Minkowski P, Höringer G, et al. Risk stratification by the virtual crossmatch: a prospective study in 233 renal transplantations. Transplant Int. 2011;24:560–569.
5. Heilman RL, Devarapalli Y, Chakrera HA, et al. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant. 2010;10:563–570.
6. Cosio FG, Amer H, Grande JP, et al. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. Transplantation. 2007;83:411–416.
7. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157–1167.
8. Moresco F, Carrera M, Goma M, et al. Early subclinical rejection as a risk factor for late chronic humoral rejection. Transplantation. 2012;93:41–46.
9. Mueller TF, Einecke G, Reeve J, et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant. 2007;7:2712–2722.
10. Einecke G, Kayser D, Vanslambrouck JM, et al. Loss of solute carriers in T cell-mediated rejection in mouse and human kidneys: an active epithelial injury repair response. Am J Transplant. 2010;10:2241–2251.
11. Edemir B, Reuter S, Borgulya R, et al. Acute rejection modulates gene expression in the collecting duct. J Am Soc Nephrol. 2008;19:538–546.
12. Foxall PJ, Melotte GJ, Bending MR, et al. NMR spectroscopy as a novel approach to the monitoring of renal transplant function. Kidney Int. 1993;43:234–245.
13. Blydt-Hansen TD, Sharma A, Gibson IW, et al. Urinary metabolomics for noninvasive detection of borderline and acute T cell-mediated rejection in children after kidney transplantation. Am J Transplant. 2014;14:2339–2349.
14. Suhre K, Schwartz JE, Sharma VK, et al. Urine metabolite profiles predictive of human kidney allograft status. J Am Soc Nephrol. 2016;24:626–636.
15. Rush D, Somorjai R, Dolenko B, et al. Validation of urine magnetic resonance spectra (UMRS) for the diagnosis of renal allograft pathology: results from the DeKAF study. Am J Transplant. 2012;12(S3):193.
16. Hauser IA, Spiegler S, Kiss E, et al. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG). J Am Soc Nephrol. 2005;16:1849–1858.
17. Matz M, Beyer J, Wunsch D, et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney Int. 2006;69:1683–1690.
18. Kamarz T, Feng P, Tomelija J, et al. Surveillance of acute rejection in baboon renal transplantation by elevation of interferon-gamma inducible protein-10 and monokine induced by interferon-gamma in urine. Transplantation. 2004;78:1002–1007.
19. Hu H, Aizenstein BD, Puchalski A, et al. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant. 2004;4:432–437.
20. Peng W, Chen J, Jiang Y, et al. Urinary fractalkine is a marker of acute rejection. Kidney Int. 2008;74:1454–1460.
21. Hirt-Minkowski P, Amico P, Ho J, et al. Detection of clinical and subclinical tubulo-interstitial inflammation by the urinary CXCL10 chemokine in a real-life setting. Am J Transplant. 2012;12:1811–1823.
22. Schaub S, Nickerson P, Rush D, et al. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant. 2009;9:1347–1353.
23. Ho J, Rush DN, Karpinski M, et al. Validation of urinary CXCL10 as a marker of borderline, subclinical, and clinical tubulitis. Transplantation. 2011;92:878–882.
24. Blydt-Hansen TD, Gibson IW, Gao A, et al. Elevated urinary CXCL10-to-creatinine ratio is associated with subclinical and clinical rejection in pediatric renal transplantation. Transplantation. 2015;99:797–804.
25. Tatapudi RR, Muthukumar T, Dachhana D, et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int. 2004;65:2390–2397.
26. Hrick DE, Nickerson P, Fornicai RN, et al. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant. 2013;13:2634–2644.

© 2016 Wolters Kluwer Ho et al
27. Hu H, Kwun J, Aizenstein BD, et al. Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation. 2009;87:1814–1820.

28. Jackson JA, Kim EJ, Begley B, et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant. 2011;11:2229–2234.

29. Rabant M, Amrouche L, Lebreton X, et al. Urinary C-X-C motif chemokine 10 independently improves the noninvasive diagnosis of antibody-mediated kidney allograft rejection. J Am Soc Nephrol. 2015;26:2840–2851.

30. Suthanthiran M, Schwartz JE, Ding R, et al. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med. 2013;369:20–31.

31. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713–723.

32. Bouatra S, Aziat F, Mandal R, et al. The human urine metabolome. PLoS One. 2013;8:e73076.

33. Xia J, Mandal R, Sinelnikov IV, et al. MetaboAnalyst 2.0—a comprehensive server for metabolomic data analysis. Nucleic Acids Res. 2012;40 (Web Server issue):W127–33.

34. Xia J, Broadhurst DI, Wilson M, et al. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics. 2013;9:280–299.

35. Møvik BHWR, Liland KHR. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.

36. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–172; discussion 207–12.

37. Ho J, Rush DN, Krokhin O, et al. Elevated urinary matrix metalloproteinase-7 detects underlying renal allograft inflammation and injury. Transplantation. 2016;100:648–654.

38. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007;24:1227–1251.

39. Motohashi H, Inui K. Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J. 2013;15:581–588.

40. Grimm PC, McKenna R, Nickerson P, et al. Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. J Am Soc Nephrol. 1999;10:1582–1589.

41. Cress AP, Fraker PJ, Bieber LL. Carnitine and acylcarnitine levels of human peripheral blood lymphocytes and mononuclear phagocytes. Biochim Biophys Acta. 1989;992:135–139.

42. Kurth L, Fraker P, Bieber L. Utilization of intracellular acylcarnitine pools by mononuclear phagocytes. Biochim Biophys Acta. 1994;1201:321–327.

43. Meekan SM, McCluskey RT, Pascual M, et al. Cytotoxicity and apoptosis in human renal allografts: identification, distribution, and quantitation of cells with a cytotoxic granule protein GMP-17 (TIA-1) and cells with fragmented nuclear DNA. Lab Invest. 1997;76:639–649.